EUVIMEDEUVIMED entdecken
Multizentrische Studie

Prevalence of co‐existent COVID ‐19‐associated pulmonary aspergillosis ( CAPA ) and its impact on early mortality in patients with COVID ‐19‐associated pulmonary mucormycosis ( CAPM )

Valliappan Muthu iD, Ritesh Agarwal iD, Shivaprakash Mandya Rudramurthy iD, Deepak Thangaraju, Manoj Radhakishan Shevkani, Atul K Patel iD, Prakash Srinivas Shastri iD, Ashwini Tayade, Sudhir Bhandari, Vishwanath Gella, Jayanthi Savio, Surabhi Madan und 45 weitere

Mycoses · 2024-05 · 67 (5)

DOI: 10.1111/myc.13745 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Mycoses, online erschienen am 20.05.2024. Verfasst von Valliappan Muthu und 56 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: COVID-19, Mucormycosis, Coinfection. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: World Health Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Data on mixed mould infection with COVID‐19‐associated pulmonary aspergillosis (CAPA) and COVID‐19‐associated pulmonary mucormycosis (CAPM) are sparse.

Objectives

To ascertain the prevalence of co‐existent CAPA in CAPM (mixed mould infection) and whether mixed mould infection is associated with early mortality (≤7 days of diagnosis).

Methods

We retrospectively analysed the data collected from 25 centres across India on COVID‐19‐associated mucormycosis. We included only CAPM and excluded subjects with disseminated or rhino‐orbital mucormycosis. We defined co‐existent CAPA if a respiratory specimen showed septate hyphae on smear, histopathology or culture grew Aspergillus spp. We also compare the demography, predisposing factors, severity of COVID‐19, and management of CAPM patients with and without CAPA. Using a case–control design, we assess whether mixed mould infection (primary exposure) were associated with early mortality in CAPM.

Results

We included 105 patients with CAPM. The prevalence of mixed mould infection was 20% (21/105). Patients with mixed mould infection experienced early mortality (9/21 [42.9%] vs. 15/84 [17.9%]; p = 0.02) and poorer survival at 6 weeks (7/21 [33.3] vs. 46/77 [59.7%]; p = 0.03) than CAPM alone. On imaging, consolidation was more commonly encountered with mixed mould infections than CAPM. Co‐existent CAPA (odds ratio [95% confidence interval], 19.1 [2.62–139.1]) was independently associated with early mortality in CAPM after adjusting for hypoxemia during COVID‐19 and other factors.

Conclusion

Coinfection of CAPA and CAPM was not uncommon in our CAPM patients and portends a worse prognosis. Prospective studies from different countries are required to know the impact of mixed mould infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19MucormycosisCoinfectionHumansMaleFemaleRetrospective StudiesMiddle AgedPrevalenceIndiaAdultPulmonary AspergillosisSARS-CoV-2AgedCase-Control StudiesLung Diseases, Fungal

Stichwörter der Autor:innen

Rhizopusaspergilluscorona virusmixed mould infectionsmouldszygomycosis

Autor:innen und Institutionen

  • Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Kovai Medical Center and Hospital, Coimbatore, India.
  • Avron Hospitals, Ahmedabad, India.
  • Sterling Hospital, Ahmedabad, India.
  • Sir Gangaram Hospital, New Delhi, India.
  • Kingsway Hospital, Nagpur, Maharashtra, India.

ORCID-Profile: Valliappan Muthu, Ritesh Agarwal, Shivaprakash Mandya Rudramurthy, Atul K Patel, Prakash Srinivas Shastri, Vinaykumar Hallur, Puneet Saxena, Kiran Kumar Kompella, Amrita Prayag

Förderung

  • World Health Organization

Zitieren

APA

Muthu, V., Agarwal, R., Rudramurthy, S. M., Thangaraju, D., Shevkani, M. R., Patel, A. K., Shastri, P. S., Tayade, A., Bhandari, S., Gella, V., Savio, J., Madan, S., Hallur, V., Maturu, V. N., Srinivasan, A., Sethuraman, N., Sibia, R. P. S., Pujari, S., Mehta, R., …, & Chakrabarti, A. (2024). Prevalence of co‐existent COVID ‐19‐associated pulmonary aspergillosis ( CAPA ) and its impact on early mortality in patients with COVID ‐19‐associated pulmonary mucormycosis ( CAPM ). Mycoses, 67(5). https://doi.org/10.1111/myc.13745

Vancouver

Muthu V, Agarwal R, Rudramurthy SM, Thangaraju D, Shevkani MR, Patel AK, et al. Prevalence of co‐existent COVID ‐19‐associated pulmonary aspergillosis ( CAPA ) and its impact on early mortality in patients with COVID ‐19‐associated pulmonary mucormycosis ( CAPM ). Mycoses. 2024;67(5). doi:10.1111/myc.13745

BibTeX
@article{Muthu2024,
  author = {Muthu, Valliappan and Agarwal, Ritesh and Rudramurthy, Shivaprakash Mandya and Thangaraju, Deepak and Shevkani, Manoj Radhakishan and Patel, Atul K and Shastri, Prakash Srinivas and Tayade, Ashwini and Bhandari, Sudhir and Gella, Vishwanath and Savio, Jayanthi and Madan, Surabhi and Hallur, Vinaykumar and Maturu, Venkata Nagarjuna and Srinivasan, Arjun and Sethuraman, Nandini and Sibia, Raminder Pal Singh and Pujari, Sanjay and Mehta, Ravindra and Singhal, Tanu and Saxena, Puneet and Gupta, Varsha and Nagvekar, Vasant and Prayag, Parikshit and Patel, Dharmesh and Xess, Immaculata and Savaj, Pratik and Sehgal, Inderpaul Singh and Panda, Naresh and Rajagopal, Gayathri Devi and Parwani, Riya Sandeep and Patel, Kamlesh and Deshmukh, Anuradha and Vyas, Aruna and Gandra, Raghava Rao and Sistla, Srinivas Kishore and Padaki, Priyadarshini A and Ramar, Dharshni and Panigrahi, Manoj Kumar and Sarkar, Saurav and Rachagulla, Bharani and Vallandaramam, Pattabhiraman and Premachandran, Krishna Prabha and Pawar, Sunil and Gugale, Piyush and Hosamani, Pradeep and Dutt, Sunil Narayan and Nair, Satish and Kalpakkam, Hariprasad and Badhwar, Sanjiv and Kompella, Kiran Kumar and Singla, Nidhi and Navlakhe, Milind and Prayag, Amrita and Singh, Gagandeep and Dhakecha, Poorvesh and Chakrabarti, Arunaloke},
  title = {Prevalence of co‐existent COVID ‐19‐associated pulmonary aspergillosis ( CAPA ) and its impact on early mortality in patients with COVID ‐19‐associated pulmonary mucormycosis ( CAPM )},
  journal = {Mycoses},
  year = {2024},
  volume = {67},
  number = {5},
  doi = {10.1111/myc.13745}
}
Kostenlos starten →